List of promising compounds in clinical trials and FDA-approved for treatment of SCD and/or cancer.

Table 1: List of promising compounds in clinical trials and FDA-approved for treatment of SCD and/or cancer.

Compound Name	Target	Function	Outcomes	Phase of Clinical Trial	Disease
Hydroxyurea	b-globin gene	Up-regulates HbF expression	Reduces the frequency of vasoocclusive episodes	FDA-approved	SCD
SCD-101	HbS	Anti-sickling	Alleviates Chronic pain and fatigue	Phase 1b	SCD
Aes-103	HbS	Anti-sickling	Modified Hb structure	Phase 1	SCD
GBT440	HbS	Anti-sickling	Enhances HbS oxygen affinity	Double-Blind phase 3	SCD
Rivipansel(GMI-1070)	Selectins	Pan-selectin inhibitor	Reduces Duration of acute pain crises, and opioid use	Randomized double-Blind phase 3	SCD
Crizanlizumab (SEG101)	P selectin	Anti-P selectin monoclonal antibody	Lowers pain crises	Phase 2	SCD
RDEA119/BAY 869766	MEK1/2	MEK1/2 inhibitor	Well-tolerated with some clinical benefit across a range of tumor types	Phase 1	Advanced metastatic solid tumor
Trametinib	MEK1/2	MEK1/2 inhibitor	Melanoma treatment	FDA-approved	BRAF-mutant melanoma
CI-1040	MEK1/2	MEK1/2 inhibitor	No clinical activity	Phase 2	NSCLC, colon pancreatic, and breast cancers
PD0325901	MEK1/2	MEK1/2 inhibitor	No clinical activity	Phase 2 (terminated)	Advanced breast and colon cancer, and melanoma
Selumetinib (AZD6244)	MEK1/2	MEK1/2 inhibitor	No significant antitum or activity	Phase 2 (terminated)	Breast cancer
GDC-0973 (XL-518,RG7421)	MEK1/2	MEK1/2 inhibitor	Partially good responses	Phase 2	BRAF-mutated both melanoma and pancreatic cancer, and breast cancer
Pimasertib (MEK162)	MEK1/2	MEK1/2 inhibitor		Phase 2	N-Ras-mutated cutaneous melanoma, and ovarian cancer
AZD8330	MEK1/2	MEK1/2 inhibitor		Phase 1	Advanced malignancies
RO5126766	MEK1/2	MEK1/2 inhibitor		Phase 1	Advanced NSCLC

Drug's named and their targets, function, clinical benefits, and their phase in clinical trial for SCD and/or cancer treatments are presented.